<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00822393</url>
  </required_header>
  <id_info>
    <org_study_id>MC-FludT.14/L</org_study_id>
    <secondary_id>EudraCT-No.: 2008-002356-18</secondary_id>
    <nct_id>NCT00822393</nct_id>
  </id_info>
  <brief_title>Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)</brief_title>
  <official_title>Clinical Phase III Trial to Compare Treosulfan-based Conditioning Therapy With Busulfan-based Reduced-intensity Conditioning (RIC) Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With AML or MDS Considered Ineligible to Standard Conditioning Regimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>medac GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>medac GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized allogeneic transplantation protocol compares i.v. Treosulfan-based
      conditioning therapy with reduced intensity i.v. Busulfan-based conditioning in adult AML and
      MDS patients at increased risk for standard conditioning therapies. The protocol is based on
      results of previous phase I/II trials evaluating Treosulfan/Fludarabine conditioning prior to
      allogeneic haematopoietic stem cell transplantation. The reference arm (reduced intensity
      i.v. Busulfan/Fludarabine) is considered to be accepted medical practice for the study
      patient population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare efficacy and safety of Treosulfan-based conditioning (test) with i.v.
      Busulfan-based reduced intensity conditioning (reference).

      The statistical aim of the study is to show non-inferiority with respect to:

      Event-free survival (EFS) within 2 years after transplantation. Events are defined as relapse
      of disease, graft failure or death (whatever occurs first).

        1. Comparative evaluation of incidence of CTC grade III/IV mucositis/stomatitis between day
           -6 and day +28

        2. Comparative evaluation of overall survival (OS) and cumulative incidence of relapse (RI)
           as well as non-relapse mortality (NRM) and transplantation-related mortality (TRM)within
           2 years after transplantation

        3. Comparative evaluation of day +28 conditional cumulative incidence of engraftment

        4. Comparative evaluation of day +28 and day +100 incidence of complete donor-type
           chimerism

        5. Comparative evaluation of cumulative incidence of acute and chronic GvHD within 2 years
           after transplantation

        6. Comparative evaluation of incidence of other CTC grade III/IV adverse events between day
           -6 and day +28

      Individual patients will be followed-up for at most 2 years after transplantation. Three
      confirmatory interim evaluations and one final analysis are planned, which allow to stop the
      trial as soon as the question of non-inferiority is answered (as outlined below). In
      addition, post-surveillance with respect to OS and EFS will be conducted one year after
      transplantation of the last randomised patient.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>within 2 years after transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparative evaluation of incidence of CTC grade III/IV mucositis/stomatitis between day -6 and day +28</measure>
    <time_frame>between day -6 and day +28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">570</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Busulfan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treosulfan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>4 x 0.8 mg/kg/d Intravenous Day -4 and -3</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treosulfan</intervention_name>
    <description>10 g/m2/d Intravenous Day -4, -3, -2</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with acute myeloid leukaemia acc. to WHO, 2008 (AML in complete remission at
             transplant, i.e. blast counts &lt; 5 % in bone marrow) or myelodysplastic syndrome acc.
             to WHO, 2008 (MDS with blast counts &lt; 20 % in bone marrow during disease history)
             indicated for allogeneic haematopoietic progenitor cell transplantation but considered
             to be at increased risk for standard conditioning therapies according to the following
             criteria:

               -  patients aged ≥ 50 years at transplant and / or

               -  patients with a HCT-CI score &gt; 2 [acc. to Sorror et al., 2005]

          2. Availability of an HLA-identical sibling donor (MRD) or HLA-identical unrelated donor
             (MUD). Donor selection is based on molecular high resolution typing (4 digits) of
             class II alleles of the DRB1 and DQB1 gene loci and molecular (at least) low
             resolution typing (2 digits) of class I alleles (i.e., antigens) of the HLA- A, B, and
             C gene loci. In case, no class I and class II completely identical donor (10 out of 10
             gene loci) can be identified, one antigen disparity (class I) and/or one allele
             disparity (class II) between patient and donor are acceptable. Conversely, disparity
             of two antigens (irrespective of the involved gene loci) cannot be accepted. These
             definitions for the required degree of histocompatibility apply to the selection of
             related as well as of unrelated donors.

          3. Adult patients of both gender, age 18 - 70 years

          4. Karnofsky Index ≥ 60 %

          5. Written informed consent

          6. Men capable of reproduction and women of childbearing potential must be willing to
             consent to using a highly effective method of birth control such as condoms, implants,
             injectables, combined oral contraceptives, IUDs, sexual abstinence or vasectomised
             partner while on treatment and for at least 6 months thereafter

        Exclusion Criteria:

          1. Patients with acute promyelocytic leukaemia with t(15;17)(q22;q12) and in CR1

          2. Patients considered contra-indicated for allogeneic HSCT due to severe concomitant
             illness (within three weeks prior to scheduled day -6):

               -  patients with severe renal impairment like patients on dialysis or prior renal
                  transplantation or S-creatinine &gt; 3.0 x ULN or calculated creatinine-clearance &lt;
                  60 ml/min

               -  patients with severe pulmonary impairment, DLCOsb (Hb-adjusted)/or FEV1 &lt; 50 % or
                  severe dyspnoea at rest or requiring oxygen supply

               -  patients with severe cardiac impairment diagnosed by echocardiography and LVEF &lt;
                  40 %

               -  patients with severe hepatic impairment indicated by hyperbilirubinaemia &gt; 3 x
                  ULN or ALT / AST &gt; 5 x ULN

          3. Active malignant involvement of the CNS

          4. HIV-positivity, active non-controlled infectious disease under treatment (no decrease
             of CRP or PCT) including active viral liver infection

          5. Previous allogeneic HSCT

          6. Pleural effusion or ascites &gt; 1.0 L

          7. Pregnancy or lactation

          8. Known hypersensitivity to treosulfan, busulfan and/or related ingredients

          9. Participation in another experimental drug trial within 4 weeks prior to day -6 of the
             protocol

         10. Non-cooperative behaviour or non-compliance

         11. Psychiatric diseases or conditions that might compromise the ability to give informed
             consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dietrich W. Beelen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Essen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helsinki University Central Hospital, Dept. of Medicine</name>
      <address>
        <city>Helsinki</city>
        <zip>00290</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Lyon</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus Dresden, Med. Klinik I</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Knochenmarktransplantation</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Malteser Krankenhaus St. Franziskus-Hospital</name>
      <address>
        <city>Flensburg</city>
        <zip>24939</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Goettingen, Haematolgie und Onkologie</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Kliniken Hamburg GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Friedrich-Schiller-Universität Jena</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Koeln, Stammzelltransplantation</name>
      <address>
        <city>Koeln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig, Haematologie, internistische Onkologie</name>
      <address>
        <city>Leipzig</city>
        <zip>04109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes-Gutenberg-Universität Mainz, III. Medizinische Klinik</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Rechts der Isar der TU München, III. Med. Klinik</name>
      <address>
        <city>Muenchen</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <zip>48129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg, 5. Medizinische Klinik</name>
      <address>
        <city>Nürnberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg gGmbH</name>
      <address>
        <city>Oldenburg</city>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stiftung Deutsche Klinik für Diagnostik</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65191</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Istvan and St. Laszlo Hospital of Budapest</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology University of Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>1-25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific Institute H. San Raffaele</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile Pescara</name>
      <address>
        <city>Pescara</city>
        <zip>65123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Umberto I Univ. La Sapienza</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Ematologica ed Unita di Terapie Cellulari 'Carlo Melzi'</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico GB Rossi (Borgo Roma), Div. di Ematologia</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Gdansk</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Silesian Medical University</name>
      <address>
        <city>Katowice</city>
        <zip>40-032</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Poland</country>
  </location_countries>
  <link>
    <url>http://www.medac.de</url>
    <description>Sponsor's homepage</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2009</study_first_submitted>
  <study_first_submitted_qc>January 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2009</study_first_posted>
  <last_update_submitted>March 26, 2018</last_update_submitted>
  <last_update_submitted_qc>March 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treosulfan</keyword>
  <keyword>Busulfan</keyword>
  <keyword>Conditioning</keyword>
  <keyword>Allogeneic</keyword>
  <keyword>Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Treosulfan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

